MicroRNA-106b在肾细胞癌中的表达及临床意义

陶令之; 李一帆; 金露; 刘家驹; 陈独群; 苏郑明; 倪梁朝; 杨尚琪; 桂耀庭; 毛向明; 来永庆

doi:10.13201/j.issn.1001-1420.2015.10.007

MicroRNA-106b在肾细胞癌中的表达及临床意义

- 1. 北京大学深圳医院泌尿外科, 北京大学深圳医院男性生殖实验室(广东深圳, 518036);
- 2. 安徽医科大学研究生院
基金项目:
国家自然科学基金(编号81101922)

广东省医学科研基金(编号A2012584)和(编号A2013606)

深圳市科技研发资金知识创新计划基础研究项目(编号JCYJ20130402114702124)

广东省重点医学学科课题基金

详细信息

通讯作者: 来永庆,E-mail:yqlord@163.com

中图分类号: R737.11

收稿日期: 2015-06-17

Expression and clinical significance of miR-106b in renal cell carcinoma

- 1. Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518035, China;
- 2. Anhui Medical University Graduate School

More Information

Corresponding author: LAI Yongqing, E-mail: yqlord@163.com

Received Date: 17 June 2015

摘要

摘要: 目的:比较microRNA-106b(miR-106b)在肾癌及癌旁正常组织之间和肾癌细胞系和正常肾细胞系之间的表达水平,并分析其表达水平与临床病理资料之间的关系。方法:采用RT-qPCR方法检测miR-106b表达量在35对肾癌组织和癌旁正常组织中的差异,并运用秩和检验方法分析肾癌组织中miR-106b表达量与患者临床病理特征之间的相关性。培养肾癌细胞系(786-O和ACHN)和正常肾上皮细胞系(HK-2)并采用RT-qPCR方法检测细胞miR-106b表达量。结果:miR-106b在肾癌组织中的表达量明显高于癌旁正常组织(P<0.01),且肾癌组织中miR-106b表达量与肾癌的组织类型有相关性(P=0.049),未发现与其他临床病理资料如年龄、性别、T分期、Fuhrman分级和AJCC临床分期有明显相关关系(P>0.05)。同时,miR-106b表达量在肾癌细胞系中也明显高于正常肾上皮细胞系(P<0.01)。结论:miR-106b在肾癌组织和细胞系中均高表达,且其在肾癌组织中的表达水平与肾癌组织类型相关,提示miR-106b与肾癌的发生和发展相关。
- miR-106b /
- 肾癌 /
- 组织类型
Abstract: Objective:To compare the expression level of miR-106b between renal cancer and adjacent normal kidney tissues (ANTs) and between cells derived from renal cancer and normal kidney and to analyze the relationship between the expression level of miR-106b and the clinicopathology.Method:Through quantitative real-time polymerase chain reaction (RT-qPCR) we determined the expression of miR-106b in 35 paired renal cancer tissues and ANTs and we analysed the relationship between miR-106b expression and clinicopathology by rank sum test. We cultivated the renal cancer cell lines (786-O and ACHN) and human normal kidney cell line HK-2 and determined the expression level of miR-106b in cells by RT-qPCR.Result:MiR-106b was up-regulated in renal cell carcinoma (RCC) tissues and cell lines compared with control normal tissues and cell line(P<0.01). And the miR-106b expression in RCC tissues was correlated with histological type (P=0.049), but there was no correlation between miR-106b expression and other clinicopathological variables such as age, sex, T stage, Fuhrman grade and AJCC staging (P>0.05).Conclusion:MiR-106b was up-regulated in both renal cancer tissues and cell lines and miR-106b expression level was related to histological type of renal cancer. It is suggested that miR-106b play a potential role in the tumorigenesis and development.
- miR-106b /
- renal cell carcinoma /
- histological type

HTML全文

参考文献(26)

[1]	Ridge C A, Pua B B, Madoff D C. Epidemiology and staging of renal cell carcinoma[J]. Semin Intervent Radiol, 2014, 31(1):3-8.
[2]	Ferlay J, Shin H R, Bray F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12):2893-2917.
[3]	Motzer R J, Bander N H, Nanus D M. Renal-cell carcinoma[J]. N Engl J Med, 1996, 335(12):865-875.
[4]	Iwamoto H, Kanda Y, Sejima T, et al. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma[J]. Int J Oncol, 2014, 44(1):53-58.
[5]	Linehan W M, Srinivasan R, Schmidt L S. The genetic basis of kidney cancer:a metabolic disease[J]. Nat Rev Urol, 2010, 7(5):277-285.
[6]	Fendler A, Stephan C, Yousef G M, et al. MicroRNAs as regulators of signal transduction in urological tumors[J]. Clin Chem, 2011, 57(7):954-968.
[7]	Oulas A, Karathanasis N, Louloupi A, et al. Finding cancer-associated miRNAs:methods and tools[J]. Mol Biotechnol, 2011, 49(1):97-107.
[8]	Maher E R. Genomics and epigenomics of renal cell carcinoma[J]. Semin Cancer Biol, 2013, 23(1):10-17.
[9]	Rydzanicz M, Wrzesiński T, Bluyssen H A, et al. Genomics and epigenomics of clear cell renal cell carcinoma:recent developments and potential applications[J]. Cancer Lett, 2013, 341(2):111-126.
[10]	Müller S, Nowak K. Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles[J]. Biomed Res Int, 2014, 2014:948408.
[11]	Slaby O, Jancovicova J, Lakomy R, et al. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy[J]. J Exp Clin Cancer Res, 2010, 29:90.
[12]	Wulfken L M, Moritz R, Ohlmann C, et al. MicroRNAs in renal cell carcinoma:diagnostic implications of serum miR-1233 levels[J]. PLoS One, 2011, 6(9):e25787.
[13]	Chow T F, Youssef Y M, Lianidou E, et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis[J]. Clin Biochem, 2010, 43(1-2):150-158.
[14]	Hui A B, Lenarduzzi M, Krushel T, et al. Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas[J]. Clin Cancer Res, 2010, 16(4):1129-1139.
[15]	Ji T, Zheng Z G, Wang F M, et al. Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients[J]. Asian Pac J Cancer Prev, 2014, 15(4):1739-1743.
[16]	Ambs S, Prueitt R L, Yi M, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer[J]. Cancer Res, 2008, 68(15):6162-6170.
[17]	Wang Y X, Zhang X Y, Zhang B F, et al. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis[J]. J Dig Dis, 2010, 11(1):50-54.
[18]	Yao Y, Suo A L, Li Z F, et al. MicroRNA profiling of human gastric cancer[J]. Mol Med Rep, 2009, 2(6):963-970.
[19]	Yu X, Wu Y, Liu Y, et al. miR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous cell carcinoma[J]. Curr Pharm Biotechnol, 2014, 15(5):503-508.
[20]	Wang X, Zhang H, Zhang A, et al. Upregulation of miR-20a and miR-106b is involved in the acquisition of malignancy of pediatric brainstem gliomas[J]. Oncol Rep, 2012, 28(4):1293-1300.
[21]	Schaefer A, Stephan C, Busch J, et al. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors[J]. Nat Rev Urol, 2010, 7(5):286-297.
[22]	Liu F, Gong J, Huang W, et al. MicroRNA-106b-5p boosts glioma tumorigensis by targeting multiple tumor suppressor genes[J]. Oncogene, 2014, 33(40):4813-4822.
[23]	Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers[J]. Br J Cancer, 2010, 102(7):1174-1179.
[24]	Zhou X, Zhang X, Yang Y, et al. Urinary cell-free microRNA-106b as a novel biomarker for detection of bladder cancer[J]. Med Oncol, 2014, 31(10):197.
[25]	Hudson R S, Yi M, Esposito D, et al. MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer[J]. Oncogene, 2013, 32(35):4139-4147.
[26]	Arabi L, Gsponer J R, Smida J, et al. Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma-reasons and consequences[J]. Genes Cancer, 2014, 5(1-2):56-63.